Every year around 500,000 people in Germany are diagnosed with cancer. German Cancer Aid relies on new treatment options in immunotherapy.
New active ingredients based on so-called low molecules, i.e. with a mass of less than 800 g/mol, are intended to offer new Treatment options. The first approved drug of this type of checkpoint inhibitor was ipimumab for the treatment of malignant skin cancer in 2011. Another checkpoint inhibitor, nivolumab, has been available as a drug for advanced lung cancer since 2015.